Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia

  • Cancer
  • Non Hodgkin Lymphoma (NHL)
  • Follicular Lymphoma
  • Leukemia
  • Chronic Lymphocytic Leukemia
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:

Completed

This trial runs in
Country
  • South Korea
Trial Identifier:

NCT03374137 ML30074

      Show trial locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      This study aims to collect clinical data, mainly focused on safety, in the local target population as per the requirement of Korea Ministry of Food and Drug Safety for market authorization. The study population comprises patients with approved local indications chronic lymphocytic leukemia (CLL) and/or follicular lymphoma (FL) in routine clinical practice after launch.

      Hoffmann-La Roche Sponsor
      N/A Phase
      NCT03374137, ML30074 Trial Identifier
      obinutuzumab Treatments
      Chronic Lymphocytic Leukemia, Follicular Lymphoma Condition
      Official Title

      Post-Marketing Surveillance of Gazyva in Treatment of Patients With Gazyva in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia Patients

      Eligibility Criteria

      All Gender
      ≥ 18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Administered obinutuzumab under the approved indications in Korea at investigator's discretion
      • Previously untreated with obinutuzumab
      Exclusion Criteria
      • Out-of locally approved indications, dosage, and administration
      • Pregnant women, breastfeeding women
      • Hepatic disease
      • Participate in other clinical trials

      For the latest version of this information please go to www.forpatients.roche.com

       

      Related Trials

      Use our search to find other trials on ForPatients in related disease areas.

      Follicular Lymphoma Chronic Lymphocytic Leukemia

      Clinical Research Explained

      Information about what clinical trials and observational studies are. Understand why you might want to take part in clinical research and why diversity in clinical research is important.

      Find out now